AHCOAdaptHealth Corp.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.
Priced for ~1% a year FCF growth. The price bakes in little to no growth.
In its normal range: P/E 16.3 vs a 20.0 median over 13 quarters (−19% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What AHCO's price assumes
Today's price asks for 0.87% free cash flow growth a year; over the last three years AdaptHealth Corp. delivered 65%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 7.2%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +0.87%
Growth the price implies · The price pays for +0.87% free cash flow growth a year for a decade; the business has delivered +65% a year over the last three.
- Price / book
- 0.90
Price / book · today's price, fiscal year to Dec 31, 2025
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 0.90
- EV / EBIToperating margin −4.5%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 0.96
- Free cash flow, trailing twelve months
- $98M
- Market capitalisation
- $1.36B
- 3-year revenue growth
- +1.6%
- 3-year free cash flow growth
- +65%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.